Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

INTRODUCTION: Multiple myeloma is a plasma cell malignancy that accounts for 1%–2% of newly diagnosed cancers. At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (mini...

Descripción completa

Detalles Bibliográficos
Autores principales: Royle, Kara-Louise, Coulson, Amy Beth, Ramasamy, Karthik, Cairns, David A, Hockaday, Anna, Quezada, Sergio, Drayson, Mark, Kaiser, Martin, Owen, Roger, Auner, Holger W, Cook, Gordon, Meads, David, Olivier, Catherine, Barnard, Lorna, Lambkin, Rhiannon, Paterson, Andrea, Dawkins, Bryony, Chapman, Mike, Pratt, Guy, Popat, Rakesh, Jackson, Graham, Bygrave, Ceri, Sive, Jonathan, de Tute, Ruth, Chantry, Andrew, Parrish, Christopher, Cook, Mark, Asher, Samir, Yong, Kwee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677008/
https://www.ncbi.nlm.nih.gov/pubmed/36396306
http://dx.doi.org/10.1136/bmjopen-2022-063037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677008/
https://www.ncbi.nlm.nih.gov/pubmed/36396306
http://dx.doi.org/10.1136/bmjopen-2022-063037

Ejemplares similares